Palonosetron
- Atc Codes:A04AA05
- CAS Codes:135729-62-3#135729-56-5
- PHARMGKB ID:135729-62-3#135729-56-5
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Substrate of
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
Brand Names
Europe
Austria: Aloxi; Belgium: Aloxi; Bulgaria: Aloxi; Cyprus: Aloxi; Czech Republic: Aloxi; Denmark: Aloxi; Estonia: Aloxi; Finland: Aloxi; France: Aloxi; Germany: Aloxi; Greece: Aloxi; Hungary: Aloxi; Ireland: Aloxi; Italy: Aloxi; Latvia: Aloxi; Lithuania: Aloxi; Malta: Aloxi; Netherlands: Aloxi; Poland: Aloxi; Portugal: Aloxi; Romania: Aloxi; Slovakia: Aloxi; Slovenia: Aloxi; Spain: Aloxi; Sweden: Aloxi; UK: Aloxi.
North America
USA: Aloxi.
Latin America
Argentina: Onicit; Brazil: Onicit; Mexico: Onicit.
Asia
Japan: Aloxi.
Drug combinations
Chemistry
Palonosetron Hydrochloride: C~19~H~24~N~2~O HCl. Mw: 332.87. (3aS)-2,3,3a,4,5,6-Hexahydro-2-[(3S)-3-quinuclidinyl]-1H-benz[de]isoquinolin-1-one monohydrochloride. CAS-135729-62-3; CAS-135729-56-5 (palonosetron)(1995).
Pharmacologic Category
Antiemetics; 5-HT~3~ Receptor Antagonists. (ATC-Code: A04AA05).
Mechanism of action
Selective 5-HT~3~ receptor antagonist, blocking serotonin, both on vagal nerve terminals in periphery and centrally in chemoreceptor trigger zone.
Therapeutic use
Prevention of chemotherapy-associated nausea and vomiting. Prevention of acute (highly-emetogenic therapy) as well as acute and delayed (moderately-emetogenic therapy) nausea and vomiting. Prevention of postoperative nausea and vomiting.
Pregnancy and lactiation implications
Teratogenic effects not observed in animal studies. There are no adequate, well-controlled studies in pregnant women. Use during pregnancy only if clearly needed. Not recommended during lactation.
Unlabeled use
Contraindications
Hypersensitivity to palonosetron or any component of the formulation.
Warnings and precautions
Hypersensitivity reactions observed rarely with intravenous administration (use with caution in allergy to other 5-HT~3~ receptor antagonists). Use with caution in risk of QT prolongation and/or ventricular arrhythmia, and in congenital long QT syndrome or other risk factors for QT prolongation (e.g. medications known to prolong QT interval, electrolyte abnormalities, and cumulative high-dose anthracycline therapy). Not intended for treatment of nausea and vomiting or for chronic continuous therapy. Use not recommended if there is little expectation of postoperative nausea and vomiting.